Vanguard Portfolio Management
CTKB icon

Vanguard Portfolio Management’s Cytek Biosciences CTKB Stock Holding History

Vanguard Portfolio Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.06M Sell
1,141,592
-1,170,266
-51% -$5M ﹤0.01% 2436
2026
Q1 		$10.1M Buy
+2,311,858
New +$10.9M ﹤0.01% 2109

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Portfolio Management's CTKB Position: Q2 2026 in Review

Vanguard Portfolio Management reduced its Cytek Biosciences (CTKB) stake by 51% in Q2 2026, selling an estimated $5M and leaving 1,141,592 shares worth $5.06M. The position accounts for ﹤0.01% of the portfolio, ranked #2436.

Vanguard Portfolio Management first reported a position in CTKB in Q1 2026 and has held it in 2 quarters since. The position peaked at $10.1M in Q1 2026. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Vanguard Portfolio Management held 1,141,592 shares of Cytek Biosciences worth $5.06M as of Q2 2026.
  • Vanguard Portfolio Management sold 1,170,266 Cytek Biosciences shares in Q2 2026, an estimated $5M.
  • Cytek Biosciences made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2436 holding.
  • Vanguard Portfolio Management first reported a position in Cytek Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Portfolio Management's Cytek Biosciences position peaked at $10.1M in Q1 2026.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.